CompletedNCT01267188
Three Doses of NBI-98854 for Tardive Dyskinesia
About this title
Read the official source — NCT01267188This study evaluated the safety and effectiveness of NBI-98854 for people with schizophrenia.
Medication studyAges 18–65Canada
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of NBI-98854 for people with schizophrenia.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- TorontoSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateJanuary 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 10
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01267188
- Official title
Show the full official title
A Phase 2, Open-Label, Dose Titration Study to Evaluate the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Toronto
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of NBI-98854 for people with schizophrenia.
Who is behind this study?
The study sponsor is Neurocrine Biosciences, a biotech company.
Did this study involve medication?
Yes. The study involved medication, including NBI-98854.
Who was this study for?
Listed age limits: 18 years to 65 years.
